TGM2 and hypertensive disorder: Despite the one-kidney DOCA–salt model not being able to induce sustained kidney damage enough for the generation of kidney fibrosis and the lack of hypertension development, the TG2 inhibitor LDN-27219 showed signs of reducing ECM deposition, elucidating the role of TG2 as a driver in early stages of kidney damage.